

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1-57. (canceled)

58. (withdrawn) A method of inhibiting endothelial cell proliferation, comprising contacting said cells with an EG-VEGF antagonist in an amount effective to inhibit cell proliferation.

59-61. (canceled)

62. (currently amended) An antagonist of EG-VEGF that inhibits ~~EG-VEGF induced~~ proliferation of adrenal cortex-derived endothelial cells induced by a polypeptide comprising amino acid residues 20-105 of SEQ ID NO:2.

63-79. (canceled)

80. (currently amended) An antagonist of EG-VEGF, wherein the antagonist comprises an antibody or antibody fragment that specifically binds EG-VEGF a polypeptide comprising amino acid residues 20-105 of SEQ ID NO:2.

81. (previously presented) The antibody or antibody fragment of claim 80, wherein the antibody or antibody fragment is a monoclonal antibody or monoclonal antibody fragment.

82. (previously presented) The antibody or antibody fragment of claim 80, wherein the antibody or antibody fragment is a chimeric antibody or chimeric antibody fragment.

83. (previously presented) The antibody or antibody fragment of claim 80, wherein the antibody is a humanized antibody or humanized antibody fragment.

84. (previously presented) The antibody or antibody fragment of claim 80, wherein the antibody fragment is a Fab, Fab', F(ab')₂, or Fv fragment.

85. (currently amended) The antibody or antibody fragment of claim 81, wherein the monoclonal antibody or monoclonal antibody fragment is produced from hybridoma cells having ATCC accession number PTA-4119, PTA-4120, PTA-4121, or PTA-4122.

86. (currently amended) The antibody or antibody fragment of claim 85, wherein the antibody or antibody fragment is a humanized antibody or humanized antibody fragment.

87. (currently amended) The antibody or antibody fragment of claim 85, wherein the antibody or antibody fragment is a Fab, Fab', F(ab')₂, or Fv fragment.

88. (previously presented) The antibody or antibody fragment of claim 80, wherein the antibody or antibody fragment inhibits EG-VEGF induced proliferation of endothelial cells.

89. (previously presented) The antibody or antibody fragment of claim 80, wherein the antibody or antibody fragment is a humanized antibody or humanized antibody fragment.

90. (previously presented) The antibody or antibody fragment of claim 89, wherein the antibody fragment is a Fab, Fab', F(ab')₂, or Fv fragment.

91-92. (canceled)

93. (currently amended) The antibody or antibody fragment of claim ~~81~~80, wherein the ~~EG-VEGF polypeptide~~ comprises ~~an~~the amino acid sequence of SEQ ID NO:2.

94. (previously presented) A composition comprising the antibody or antibody fragment of claim 80 in admixture with a carrier.

95. (previously presented) The composition of claim 94, wherein the carrier is a pharmaceutically acceptable carrier.

96. (previously presented) The composition of claim 94, wherein the antibody or antibody fragment is a monoclonal antibody or monoclonal antibody fragment.

97. (previously presented) The composition of claim 94, wherein the antibody or antibody fragment is a chimeric antibody or chimeric antibody fragment.

98. (previously presented) The composition of claim 94, wherein the antibody or antibody fragment is a humanized antibody or humanized antibody fragment.

99. (previously presented) The composition of claim 94, wherein the antibody or antibody fragment is a Fab, Fab', F(ab')₂, or Fv fragment.

100. (currently amended) The composition of claim 96, wherein the monoclonal antibody or monoclonal antibody fragment is produced from hybridoma cells having ATCC accession PTA-4119, PTA-4120, PTA-4121, or PTA-4122.

101. (previously presented) The composition of claim 100, wherein the antibody or antibody fragment is a humanized antibody or humanized antibody fragment.

102. (previously presented) The composition of claim 100, wherein the antibody or antibody fragment is a Fab, Fab', F(ab')₂, or Fv fragment.

103. (previously presented) The composition of claim 94, wherein the antibody or antibody fragment inhibits EG-VEGF induced proliferation of endothelial cells.

104. (previously presented) An article of manufacture, comprising:

- (a) a container;
- (b) a label on the container; and
- (c) the composition of claim 95.

105. (new) An antibody or antibody fragment that competes with a monoclonal antibody produced from hybridoma cells having ATCC accession PTA-4119, PTA-4120, PTA-4121, or PTA-4122 for binding to a polypeptide comprising amino acid residues 20-105 of SEQ ID NO:2.